BioSpace News Archive

Little is known about the origins of manikins—small anatomical sculptures thought to be used by doctors four centuries ago—but now advanced imaging techniques have offered a revealing glimpse inside these captivating ivory dolls.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make the following presentations in December

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced it will present at the Evercore ISI 2nd Annual HealthCONx Conference

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that its Board of Directors has elected John Kelley to serve as non-executive board Chair, effective November 25, 2019

A live audio webcast of the presentations will be available on the Investors section of the company’s website, www.rocketpharma.com.

Eve & Co Incorporated (the “Company” or “Eve & Co”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce its interim financial results for the three and nine months ended September 30, 2019.

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) for pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor, as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, chief executive officer of Menlo Therapeutics, will provide a corporate update via a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference to be held in New York on December 03, 2019 at 4:00 pm ET.

Viracta is a precision oncology company targeting virus-associated malignancies.

Researchers are trying to identify injury patterns and predict future outcomes for victims of gun violence who are seen in the emergency room and later readmitted to the hospital, according to research being presented next week at the annual meeting of the Radiological Society of North America.